Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones June 30, 2026
Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones May 14, 2026
Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results March 24, 2026
Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma December 18, 2025
Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results November 3, 2025
Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results November 3, 2025
